Norgine’s Intellectual Property (IP) Department covers not only established products but also the product pipeline (both internally- and externally-derived). Accordingly, the IP Department provides significant input to project teams and product lifecycle management, plus business development teams analysing potential new opportunities, and is valued for its scientific expertise and commercial outlook.
This leads to an IP portfolio comprising an unusually broad assortment of IP-related matters, including potential IP infringements and US litigation; European oppositions; negotiations with third parties relating both to freedom-to-operate and protection; watching competitor activity and taking defensive action, as well as being keenly protective. Norgine pursues the full remit of IP, being aware of the value not only of patents and trademarks, but also of copyright, design right and related IP rights.
To support this global as well as legal spread, Norgine’s IP department is supported by highly qualified and experienced consultants and specialists around the world and these, together with Norgine’s expanding and pharma-experienced in-house personnel, make for an increasingly effective and expert team. In addition, the team is often called upon to contribute to, advise and develop IP strategy on the IP portfolio of Norgine’s business partners, and works in close co-operation with such external IP professionals on joint projects.
The mission of Norgine’s IP Department is to:
Support Norgine’s long-term vision;
- Assist Norgine to maximise and manage benefits from its activities (particularly in the Commercial and Development arenas);
- Assist Norgine to minimise and manage any risks of adverse consequences of its actions (such as litigation or barriers to pursuing its activities); and
- Maintain and enhance Norgine’s reputation